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a  b  s  t  r  a  c  t
SLC6  family  members  and  ABC  transporters  represent  two  extremes:  SLC6  transporters  are  conﬁned  to
the membrane  proper  and  only  expose  small  segments  to the  hydrophilic  milieu.  In ABC  transporters
the  hydrophobic  core  is connected  to a large intracellular  (eponymous)  ATP  binding  domain  that  is  com-
prised  of  two  discontiguous  repeats.  Accordingly,  their folding  problem  is  fundamentally  different.  This
can be  gauged  from  mutations  that impair  the  folding  of the  encoded  protein  and give rise  to  clini-
cally  relevant  disease  phenotypes:  in SLC6  transporters,  these  cluster  at the  protein–lipid  interface  on
the  membrane  exposed  surface.  Mutations  in ABC-transporters  map  to the  interface  between  nucleotide
binding  domains  and  the  coupling  helices,  which  provide  the  connection  to the  hydrophobic  core.  Folding
of  these  mutated  ABC-transporters  can  be corrected  with  ligands/substrates  that  bind  to the  hydrophobic
core.  This  highlights  a pivotal  role  of the coupling  helices  in  the  folding  trajectory.  In  contrast,  insights  into
pharmacochaperoning  of SLC6  transporters  are  limited  to monoamine  transporters  – in  particular  the
serotonin  transporter  (SERT)  – because  of  their  rich  pharmacology.  Only  ligands  that  stabilize  the  inward
facing  conformation  act as  effective  pharmacochaperones.  This indicates  that  the  folding  trajectory  of
SERT  proceeds  via  the  inward  facing  conformation.  Mutations  that  impair  folding  of SLC6  family  mem-
bers can  be transmitted  as  dominant  or recessive  alleles.  The  dominant  phenotype  of the  mutation  can
be  rationalized,  because  SLC6  transporters  are  exported  in  oligomeric  form  from  the endoplasmic  retic-
ulum (ER).  Recessive  transmission  requires  shielding  of the  unaffected  gene  product  from  the  mutated
transporter  in  the  ER.  This  can be accounted  for by a chaperone-COPII  (coatomer  protein  II)  exchange
model,  where  proteinaceous  ER-resident  chaperones  engage  various  intermediates  prior  to  formation  of
the  oligomeric  state  and  subsequent  export  from  the  ER.  It  is  likely  that the  action  of  pharmacochaperones
ulateis  contingent  on  and  mod
. Introduction
Many (monogenic) diseases result from point mutations that
ead to aberrant folding of a protein. In fact, the term molec-
lar medicine can be traced back to the efforts of Max  Perutz
o solve the structure of hemoglobin and of Linus Pauling
nd coworkers to understand the defect underlying sickle cell
nemia [1]. Folding diseases may  be rare by comparison to other
Abbreviations: ABC transporters, ATP-binding cassette containing transporters;
AT, dopamine transporter; ER, endoplasmic reticulum; GAT, GABA transporter
ith 4 isoforms (GAT-1, GAT-2, GAT-3, GAT-4); NBD, nucleotide binding domains;
ET, norepinephrine transporter; SLC6, solute carrier-6; SERT, serotonin trans-
orter.∗ Corresponding author. Tel.: +43 1 40160 31371; fax: +43 1 40160 931300.
E-mail address: michael.freissmuth@meduniwien.ac.at (M.  Freissmuth).
043-6618      © 2013 The Authors. Published by Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.phrs.2013.11.009
Open access under CC BY license.d  by  these  chaperones.
©  2013  The  Authors.  Published  by Elsevier  Ltd.  
widespread afﬂictions that ﬁgure prominently in health care bud-
gets such as diabetes mellitus, obesity and coronary heart disease.
However, as pointed out by Sir Archibald Garrod some 75 years
ago, major scientiﬁc advances have come from the study of rare
diseases [2]. Understanding protein folding remains a fascinat-
ing challenge, which is succinctly illustrated by the Gedanken
experiment of Cyrus Levinthal [3]. Its insights can be recapitu-
lated in a back-of-the-envelope calculation: (i) for the sake of
simplicity, assume that the two  bonds per amino acid, which
deﬁne the peptide backbone of a protein, can exist in two  sta-
ble states (e.g., the angles that deﬁne an -helix and -strand).
(ii) New conformations can be visited in 0.1 ps, i.e. at a rate
at which single bonds orient (10−13 s−1). Hence, a protein can
explore 1013 states in one second. (iii) Under these assump-
tions, an average protein of some 400 amino acids has to sample
Open access under CC BY license.some 2400 (≈10120) conformational states in the absence of
any additional constraint. In other words, exploring these states
requires 10107 s. It is evident that this is an implausible time
frame, for the currently estimated age of the known universe
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s 4.41 × 1017 s (1.4 × 1010 years). This discrepancy – referred
o as the Levinthal paradoxon – proves that the folded struc-
ure of a protein is reached via a limited set of trajectories
ather than a random, unbiased search of all possible conforma-
ions.
The folding trajectories of polytopic membrane proteins are
ubject to a number of constraints: (i) insertion of the nascent
olypeptide chain into the SEC61 translocon channel restricts the
ovement of amino acid side chains and limits the search space. (ii)
ransmembrane segments exit via a lateral gate of the translocon
nto lipid bilayer. This gate allows for passage of one or at most two
ransmembrane segments [4]. (iii) The milieu of the lipid bilayer
s anisotropic. The presence of charged residues within the trans-
embrane segment, for instance, imposes a high energetic cost
5].
Transmembrane helices are typically 21–22 residues long [6].
he conformationally important backbone of a single transmem-
rane helix has 315–330 degrees of freedom and can – according
o the concept outlined above – sample ∼106 conformations.
olding of single transmembrane helices in the SEC61 translocon
hannel occurs on the time scale of peptide chain synthesis or
aster. Once the transmembrane helix is inserted into the mem-
rane, the biophysical properties of the membrane environment
ramatically restrict this available search space: to a ﬁrst approx-
mation, (i) the number of accessible conformations is limited
o only the all-helical state. (ii) The relevant degrees of free-
om are reduced to 4, as the helix can only diffuse in the plane
f the membrane (x and y), rotate along its main axis, and tilt
elative to the plain of the membrane. Diffusion of helices that
re connected by loops is a slow process. However, the search
pace is dramatically reduced by the steep drop in the number
f degrees of freedom and in the number of accessible conforma-
ions.
Pharmacochaperoning is – by deﬁnition – linked to the prob-
em of protein folding. The question arises: why should it be of
nterest to study pharmacochaperoning of ABC-transporters3 and
LC6 transporters? From a medical perspective, these two  classes
f transporters are highly relevant to pharmacotherapy either as
rug targets (in particular the SLC6 family members SERT, NET,
AT, GAT-1) or as efﬂux pumps (ABC-transporters). In addition,
utations in ABC transporters are the cause of monogenic diseases
ther than the paradigmatic folding disease cystic ﬁbrosis (e.g.,
holestasis, gout). In addition, these two classes illustrate the fold-
ng problem of dynamic polytopic membrane proteins. They have
2 or more transmembrane segments. They are thought to undergo
ajor conformational changes and thus domain motions during
he transport cycle. This raises the question of which conforma-
ions are visited by the folding trajectory. Finally, SLC6 transporters
nd ABC-transporters are representative two extremes: in SLC6
amily members, the hydrophobic core comprises the bulk of the
rotein, intracellular and extracellular segments are small by com-
arison. This conﬁnes the folding problem to the membrane. In
ontrast, the folding trajectory of ABC-transporters must accom-
odate both and the folding of the large intracellular domains
ust be coupled to that of the transmembrane segment. In fact,
utations associated with folding defects of ABC transporters clus-
er at the interface between the transmembrane domain and the
BDs (see below). This highlights the Achilles heel of ABC trans-
orters in the folding trajectory. Here we argue that experimental
pproaches to pharmacochaperoning these transporters may  pro-
ide insights into the folding process or at the very least allow
or deﬁning the problem. We also examine the conjecture that
ommonly used drugs may  also act as pharmacochaperones when
dministered for therapeutic or recreational purposes [7]. Finally,
n the long run, pharmacochaperoning may  be used to correct fold-
ng diseases.Research 83 (2014) 63–73
1.1. Folding-deﬁcient versions of SLC6 transporters
The human genome encodes 19 SLC6 transporters. SLC6A10
is thought to be a pseudogene. Hence the numbering extends
from SLC6A1 (i.e., GAT-1) to SLC6A20 (i.e., the renal imino acid
transporter). Human diseases appear to be rarely associated with
mutations in these genes. This can be illustrated with the gene
encoding GAT1: the NCBI database lists more than 1000 single
nucleotide polymorphisms in the human SLCA1 gene. Seventeen
of these result in non-synonymous substitutions and thus give rise
to coding variants of GAT-1. It is at present not known, if one of
these SNPs are related to a clinically relevant phenotype. However,
there are some examples of (monogenic) diseases and clinically rel-
evant phenotypes that can be linked to mutations in SLC6-family
genes (Table 1); there are also less well-deﬁned phenotypes that
may  eventually be found to arise from defective folding; pertinent
examples are also listed in Table 1.
It is worth noting that mutations in SLC6 family members
can be transmitted in both, an autosomal dominant and a reces-
sive manner. It is trivial to understand why  recessive alleles only
cause symptoms in homozygous (or compound homozygous) indi-
viduals: clinical symptoms only appear in the total absence of a
transporter.
A dominant negative phenotype can be envisaged, if the
mutated transporter forms a complex with the product of the
unaffected allele and precludes its surface expression. This is for
instance evident in NET and GLYT2, where the mutated versions
NET-A457P [8] and GLYT2-S510R [21] retain the corresponding
wild type transporter within the cell (see Table 1). SLC6 family
members form oligomers [44]. Hence, dominant negative effects
can be readily rationalized. However, this model does not account
for recessive transmission, which is observed for instance in DAT
mutations associated with infantile dystonia/parkinsonism [15,16].
We mapped the residues that cause folding deﬁciency onto
a common structural scaffold, i.e., a recently published hDAT
structure [45]. This shows that the mutations are not randomly
distributed (Fig. 2, color coded by transporter). The largest group
clusters at the protein–lipid interface on the membrane exposed
surface of the transporter. Most of these mutations are conserva-
tive in amino acid substitution, retaining the hydrophobic property
of the residue. Polarity changes are therefore not expected to add
a signiﬁcant destabilizing energy to the folding process. Interac-
tions with other proteins within the membrane are not expected to
be severely affected, because dispersive hydrophobic interactions
are rather unspeciﬁc and because hydrophobicity driven complexes
have large interaction surfaces stabilized by cumulative contribu-
tions. What could then be at the origin of their effect? Almost all
of these disease causing mutations change the helical properties of
the mutated residue. It is therefore conceivable that helical stabil-
ity is affected, which links these mutations directly to the protein
folding and stability.
A second group of mutations clusters at helix crossing motifs
or affect helix packing, thereby destabilizing the global structure
of the transporter. Some mutations linked to diseases are found
in water exposed loops. These are all found at critical position of
structural motifs. Their mutation is expected to reduce protein sta-
bility. One mutation is located close to the Sec24 interaction motif
(residue K605N of SERT]). It may  affect recognition of SERT by
Sec24C.
A small number of mutations are expected to have a strong
effect on the conformational equilibrium. This has for example been
shown for the completely conserved arginine in the outer vestibule
on transmembrane helix 1. In the inward facing state, this arginine
forms a salt bridge across the outer vestibule with an aspartate
or glutamate in transmembrane helix 10. Hartnup disease that
results in dermatitis and seizures is caused by a mutation of this
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Table 1
Mutations in human SLC6 transporters.
Gene Protein name Candidate pathogenic
coding variants/missense
mutationsa
Disease Change of function Altered expression
SLC6A1 GAT-1 ? ? ? ?
(GABA  transporter-1)
SLC6A2 NET
(norepinephrine transporter)
F528C Orthostatic intolerance/postural
hypotension
Reduced afﬁnity for
desipramine [8,9]
R121Q, N292T, A369P,
A457P, I549T
Orthostatic intolerance/postural
hypotension
Reduced surface expression/
ER retention; (autosomal
dominant) (A457P) [8,9]
SLC6A3 DAT
(dopamine transporter)
V382A ADHD (attention-deﬁcit hyperactivity
disease)
Reduced surface expression
[10]
A559V, T356M, Transport cycle mutant
(exaggerated efﬂux)
[11–13]
R615C altered microdomain/
ﬂotillin association [14]
V158F, L224P, G327R,
L368Q, P395L, R521W,
P529L, P554L
Childhood (recessive)
parkinsonism-dystonia
ER-retention, reduced surface
expression [15,16]
SLC6A4 SERT
(serotonin transporter)
G56A Autism, Asperger syndrome and
obsessive-compulsive disorderb
Enhanced expression [17]
I425V, I425L, F465L, L550V,
K605N
I425V: enhanced uptake/gain
of function [17–19]; other
mutations not characterized in
functional assays
SLC6A5 GLYT2
(glycine transporter-2)
>15 mutations:
e.g. A89E, A275T, L306V,
W482R, S510R Y705C
Hyperekplexia/startle disease [21–23] ER-retention/reduced surface
expression [21,23,24]
SLC6A6 TAUT
(taurine transporter)
? ?
Suspected involvement in retinal
degeneration based on murine model
SLC6A7 PROT
(brain-speciﬁc proline transporter)
? ?
Gene deletion suspected to contribute to
intellectual disability [25]
SLC6A8 CT1
(creatine transporter-1)
>21 missense mutations X-linked mental retardation [26–29] No mutation
documented to lead to
ER retention
SLC6A9 GLYT1
(glycine transporter-1)
? ?
Suspected involvement in glycine
encephalopathy/non-ketotic
hyperglycinemia based of murine model
SLC6A11 GAT3
(GABA-transporter-3)
? ?
Polymorphism associated with
neuroleptic-induced tardive dyskinesia
[30]
SLC6A12 BGT1
(betaine-GABA transporter-1)
? ?
Polymorphisms association with negative
symptoms in schizophrenia [31] and
aspirin-intolerant asthma [32]
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Table 1 (Continued)
Gene Protein name Candidate pathogenic
coding variants/missense
mutationsa
Disease Change of function Altered expression
SLC6A13 GAT2
(GABA-transporter-2)
? ?
Polymorphisms association with chronic
kidney disease [33]
SLC6A14 ATB0
transporter for neutral, cationic
amino acids
? ?
Polymorphisms association with increased
risk for meconium ileus in newborns with
cystic ﬁbrosis [34] and with obesity [35,36]
SLC6A15 B(0)AT2 transporter for large
neutral amino acids
T49A, K227N, L260Pc,
G268Rc, D278Vc, A400V,
L421P, I500T, N591D,
A601T, E684D, G710R
Association with increased risk for major
depression
T49A and A400V result
in increased proline
uptake) [37]
None of the variants impede
surface expression
SLC6A16 NTT5
orphan sodium- and
chloride-dependent
neurotransmitter transporter
? ? ? ?
SLC6A17 NTT4/XT1
synaptic vesicle neutral amino acid
transporter
? ? ? ?
SLC6A18 B0AT3
renal neutral amino acid
transporter/glycine transporter
G79S, L478P [should
probably be P478L
mutation], G496R
Contribution to
iminoglycinuria/hyperglycinuria if one
allele of SLC36A2 is inactivated [38]
No evidence for trafﬁcking
defect of L478P but greatly
reduced surface expression of
G79S and G496R
SLC6A19  B0AT1
renal and intestinal amino acid
transporter
R57C, A69T, D173N, L242P,
P265L, G284R, S303L,
E501K
Hartnup disease (dermatitis and seizures)
[39–41]
D173N, L242P, E501K-reduced
activity/surface expression;
surface expression contingent
on interaction with
collectrin/ACE-2
(angiotensin-converting
enzyme-2) [42,43]
SLC6A20 XTRP3
proline imino transporter
T199M Contributes to iminoglycinuria if one allele
of  SLC36A2 is inactivated [38]
Impairs transport but
not surface targeting
[38]
a Mutations that result in frame shifts and/or premature termination, changes in splice acceptor sites, etc. are not listed.
b The monogenic association of the I425V mutation with obsessive-compulsive disorder has been questioned [20].
c Residues of isoform 2 that has a different sequence between residue 253 and 289; downstream residues are missing, effectively truncating the sequence after transmembrane helix 5.
P. Chiba et al. / Pharmacological Research 83 (2014) 63–73 67
Fig. 1. A chaperone-COPII-exchange model for SLC6 family members in the ER. Upon exit from the SEC61 channel (not shown), SLC family members are ﬁrst shielded
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clude the delivery of incompletely folded proteins to the plasma
membrane. Accordingly, it is not surprising that the C-terminus
plays a role in folding. In fact, the recently solved structure
of an insect DAT shows that the C-terminus folds back and
Fig. 2. Structural mapping of disease causing mutation that are linked to deﬁcien-y  luminal chaperones (shown here as calnexin, CNX) and cytosolic heat-shock pr
rotein-90 from the C-terminus unmasks the SEC24 binding site in the C-terminus 
onformation, it is relayed to the ER-associated degradation (ERAD) via the recruitm
rginine residue to cysteine in the B0AT1 amino acid transporter
39–41]. Conformation affecting mutations will have a dual effect:
hey ought to impair protein function. In addition, they are likely
o be recognized by the quality control machinery of the ER: the
utant proteins are structurally less stable; hence they are pre-
icted to switch readily between states. This makes the protein
ore susceptible for ubiquitination and degradation.
The effect of substrate binding to the conformational equilib-
ium has been directly examined in the bacterial homolog LeuTAa
46] using single molecule FRET. The transporter was shown to have
 fast conformational exchange between the inward and the out-
ard facing conformation and binding of substrate was found to
tabilize the protein in one conformation.
.2. A macroscopic model for pharmacochaperoning of SLC6
amily members
We  propose a model that accounts for both, dominant and reces-
ive transmission and also makes testable predictions about the
ctions of pharmacochaperones and chemical chaperones (Fig. 1).
he model posits that SLC6 transporters engage luminal pro-
einaceous chaperones (e.g., calnexin, CNX in Fig. 1). In addition,
he C-terminus engages a cytosolic heat-shock-protein relay (HSP
n Fig. 1). Upon release of lumenal chaperones, the transporters
ligomerize, adopt their ﬁnal stable conformation and release the
eat-shock protein from the C-terminus. This renders the binding
ite for SEC24C accessible and allows for ER export of the folded
ransporter. Conversely, if the transporter fails to reach a stably
olded conformation, it is eventually subjected to ubiquitination
via an unidentiﬁed E3-ligase), dislocated/retrotranslocated and
ubjected to ER-associated degradation (left hand part in Fig. 1).
he model is adapted from that put forth to explain trafﬁcking of
he A2A-receptor through the early secretory pathway [47] and is
ased on the following – albeit circumstantial – evidence:
(i) Oligomer formation is required for ER export of SLC6 trans-
porters. Oligomerization-deﬁcient mutants are retained in the
ER [48,49]. Mutants, in which the C-terminus is truncated and
thus the SEC24-binding site eliminated, act as dominant neg-
ative and retain the wild type transporter in the ER [50]; the
same is true for fragments of the transporter [51].
ii) In the ER, GAT1, SERT and DAT are engaged not only
by the lumenal (i.e. Ca2+-binding lectin) domain of lectin,
the transmembrane domain also shields the protein [52].
This peptide-based interaction is most pronounced with an
oligomerization-deﬁcient version of GAT1 [52]. Conversely, (HSP). Release of CNX allows for oligomerization; release of cytosolic heat-shock
los for ER export of oligomeric transporters. If the transporter fails to reach a stable
f an E3-ligase.
coexpression of lumenal chaperones increases the production
of mature SERT in heterologous expression systems up to 3-fold
[53].
iii) The binding site for the SEC24 (the cargo receptor of the
coatomer-II/COPII complex) resides in the C-terminus of GAT-1
[54], SERT and other transporters such as NET, DAT, GLYT1 and
GAT3 [55,56].
iv) In SERT, discrete mutations in the C-terminus, including the
SEC24 binding site, result in folding defects [57]. Presumably,
this phenotype reﬂects an acquired trait: bacterial transporters
are inserted directly into their target membrane (i.e., the inner
membrane of bacteria). Hence, they do not require any C-
terminal quality control. In contrast, eukaryotic transporters are
synthesized in the ER. Prior to reaching their target membrane
(i.e., the cell surface), they must undergo quality control to pre-cies in protein folding. The transmembrane domain DAT is shown as representative
member of the SLC6 family from its extracellular site. Residues identiﬁed in the
SLC6A transporter family are mapped to the corresponding position in the DAT,
identiﬁed by colored spheres of their respective C atom. Most residues cluster in
a  ring structure close to are at the membrane exposed surface of the transporter.
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Fig. 3. Structural stability analysis the extracellular loop 2. Fluctuations (quantiﬁed
as Root Mean Square Fluctuations or RMSF) around the equilibrium position contain
information on structural stability. The larger the RMSF, the larger the ﬂuctuations
and  therefore the lower the structural stability. The black line shows the RMSF of the
properly folded DAT transporter, calculated for a 20 ns long trajectory. Ten additional8 P. Chiba et al. / Pharmacolo
interacts with intracellular loop 1 [58]. We  therefore posit that
the C-terminus is ﬁrst occupied by a heat-shock protein-relay
(HSP40–HSP70). We  therefore posit that the C-terminus is ﬁrst
occupied SEC24. The chemical chaperone 4-phenylbuytrate (4-
PB), which alters the expression of heat-shock proteins in a
differential way and thus affects the heat-shock protein relay,
increases the expression of SERT [59].
v) Predictably non-speciﬁc chemical chaperones such as 4-PB
[59], dimethylsulfoxide (DMSO) and glycerol effectively rescue
mutants of SERT [58]. In contrast, pharmacochaperoning shows
exquisite speciﬁcity: the only effective ligand which works is
ibogaine (CID 442108) [59]. This indicates that the folding tra-
jectory proceeds via the inward facing conformation, because
ibogaine binds selectively to and stabilizes the inward facing
state in the transport cycle [60]. In fact, the inward facing state
is actually also favored by the ionic gradients in the ER.
Based on this hypothetical model, the following testable predic-
ions can be made:
(i) Recessive mutations are stalled in a monomeric state. Their
expression may  be increased by interfering with ERAD, with
lumenal and cytosolic chaperones (i.e., inhibitors of HSP70
and/or HSP90) and possibly by the addition of pharmacochap-
erones.
(ii) Autosomal dominant mutations are stalled in a dimeric state:
depletion of calcium (e.g., by thapsigargin to suppress func-
tional calnexin) ought to be irrelevant to their ER export, but
compounds that bind to and stabilize the inward facing con-
formation ought to promote surface expression.
iii) Finally, compounds that bind to the outward facing conforma-
tion are unlikely to act as pharmacochaperones. All inhibitors
of SLC6 family members (but ibogaine) that are used either
for therapeutic or recreational purposes bind preferentially to
the outward facing conformation. It is therefore not surpris-
ing that upregulation of transporters has not been observed
upon chronic administration of tricyclic antidepressants, SSRIs,
cocaine, etc.
.3. A microscopic model for folding of SLC6 family members
The acid test for our understanding the folding trajectory is
hat it can be simulated. Structures are available for LeuTAa in
everal conformations. In addition, the structure of an insect
opamine transporter has recently been solved in an inhibitor-
locked outward-facing conformation [58]. The folding problem
ay  therefore become amenable to computational approaches.
t is obviously impossible to reach the folded structure from the
rimary sequence but it should be possible to determine which
orces govern the assembly of helical transmembrane segments,
ow charges are best shielded from the lipid environment when
elices are released from the SEC61 channel into the lipid envi-
onment of the membrane and how the ﬁnal stable conformation
s stabilized by those segments that are exposed to the aqueous
ilieu. This includes the intracellular and extracellular loops and
he C-terminus; the N-terminus appears dispensable, because it
an be truncated without impairing surface expression [61]. As a
tarting point, the problem may  be approached by examining the
ffect of mutations that are known to preclude surface expression
y causing ER retention and subsequent degradation of the protein.
lternatively, it is also possible to examine the effect of ther-
ostabilizing mutations [62]. The effect of mutation or imperfecttructural models can be directly studied using molecular dynam-
cs simulations. An example of such an exercise is shown in Fig. 3:
sing a model of DAT, we studied the stability of the transporter
n a membrane environment [45]. The template LeuTAa used fortrajectories of model, where the ﬁrst part of the extracellular loop 2 between residue
173  and residue 202 was not properly modeled show consistent higher RMSF values.
The  regions of low RMSF coincide with helical structure elements.
model building has a much shorter extracellular loop 2 (EL2) and
cannot serve as a template for this loop. In the new drosophila DAT
used for crystallization a large part of this loop was  removed. Fig. 3
shows a structural mobility analysis (ﬂuctuation around the equi-
librium conformation quantiﬁed as Root Mean Square Fluctuation
or RMSF) of the EL2 (residue 172–237) from 20 ns long simula-
tions. The correctly folded loop (shown in black) has a substantially
lower mobility in the region of the EL2, where the LeuTAa tem-
plate could not serve as a template (residue 173–202). The ﬁrst part
involves a highly conserved tryptophan residue (W184 in DAT). If
mutated, surface expression is abolished [63]. Trajectories showed
large mobility and an unstable loop, when this tryptophan was not
properly positioned. Residue H193 of DAT is part of a zinc binding
site. Only if properly assembled, the residues coordinating remain
next to the zinc ion. Otherwise, they undergo large movements.
1.4. ABC-transporters
ATP binding cassette (ABC) proteins are found in all extant
phyla. In humans 48 genes code for ABC proteins, which on basis
of sequence similarity have been classiﬁed in seven subfamilies.
Most of these ABC proteins have been shown to be involved in the
movement of cargo across biological membranes, but other func-
tions include ion conductance and ion channel regulation. Several
ABC transporters, primarily P-glycoprotein, multidrug resistance
protein and breast cancer related protein are involved in drug
transport and therefore play a key role in drug disposition. 22
ABC-proteins have been linked to more than 27 human disease
etiologies, whereby the malfunction of a single ABC protein occa-
sionally leads to more than one disease entity [64].
1.5. Several ABC exporters share a common fold
In recent years higher resolution crystal structures of ABC
exporters have become available. These include SAV1866, a
multidrug transporter from S. aureus [65], C. elegans ABCB1 [66],
mouse mdr1a [67], the human ABCB10 transporter [68] and the
lipid A transporter MsbA [69]. These structures indicate a common
architecture of several prokaryotic and mammalian transporters,
including the ABCB subfamily members. This paradigmatic fold,
which was ﬁrst described for SAV1866 [65] and subsequently
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Fig. 4. Mapping of selected folding deﬁcient mutations of the ABC transporter family on a structural model of the inward facing conformation of human P-pg (template C.
elegans  ABCB1 (PDB ID: 4F4C)). The N-terminal half of the transporter is colored in cyan, the C-terminal half in dark blue. Panel A shows the paradigmatic fold ﬁrst reported for
SAV1866 and subsequently found to be shared with MsbA, mouse mdr1a, and human ABCB10. Fully assembled transporters show a domain swapped architecture whereby
intracellular loop 2 (connecting helices 4 and 5 of TMD1) interacts with NBD2, while ICL4 of TMD2 interacts with NBD1. Residues 951–953 photolabeled by propafenones
binding  to the transporter in mode 2 are highlighted in magenta. Location of selected disease causing mutations are shown in pink yellow and green in VDW rendering. The
residue  shown in pink, yellow and green are found mutated in one, two or three ABC transporter, respectively. All disease causing mutations are projected into the P-gp
homology model based on sequence alignments. 1: deltaF490 (ABCB1), dF508 (ABCC7), 2: I507 (ABCC7), Q141K (ABCG2); 3: E297G (ABCB11); 4: R1128 (ABCB11) and R1314
(ABCC6)  and 5: R1153 (ABCB11), R1339 (ABCC6) and R1418 (ABCC7). Panel B shows a close up of the transmission interface in a side view of NBD2. Positions of mutations 3,
4  and 5 can be appreciated to affect either intracellular loop 2 or NBD2. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version  of the article.)
Table 2
Mutations in ABC transporters.
Gene Protein name Pathogenic coding variants Phenotype
ABCA1 CERP (cholesterol efﬂux
regulatory protein)
A1046D (C-term. -helix of NBD1) [72]
R2004K (N-term. -helix of NBD2) [73]
Tangier disease (HDL
deﬁciency)
ABCA3 N568D (F1-type core domain, NBD1)
[74]
Neonatal respiratory distress
syndrome
ABCB4  MDR3 I541F (C-term. -helix of -helical domain, NBD1) [75] PFIC3 (progressive familial
intrahepatic cholestasis type 3)
ABCB11 BSEP (bile salt export
pump)
E297G (coupling helix 4, TMD2) [76]
D482G (antiparallel domain of NBD1) [76]a
PFIC2 (progressive familial
intrahepatic cholestasis type 2)
ABCC2  cMOAT (canalicular
multispeciﬁc organic anion
transporter)
R768W (N-term. -helix of -helical domain of NBD1) [77]
A1450T (N-term. -helix of -helical domain of NBD2) [78]
Dubin–Johnson syndrome
ABCC6 MOAT-E (multispeciﬁc
organic anion transporter)
R1138Q (coupling helix 4, TMD2) [79]
R1339C (F1-type core domain NBD2) [79]
Pseudoxanthoma elasticum
ABCC7 CFTR (cystic ﬁbrosis
transmembrane
conductance regulator
F508 [reviewed in 80]b I507 (N-term. -helix of -helical
domain of NBD1) [reviewed in 80]
N1303 (N-term. -helix of -helical domain of NBD2)
[reviewed in 80]
L1065P (coupling helix 4, TMD2) [reviewed in 81]
Cystic ﬁbrosis
ABCC8 SUR (sulfonyl urea
receptor)
R1493W (C-term. -helix of -helical domain NBD2) [82] Familial hyperinsulinism
ABCG2 BCRP (breast cancer
resistance protein)
Q141Kc (N-term. -helix of -helical domain of NBD1) [83] Gout
This table lists representative examples of phenotypes, which are characterized by decreased surface expression. The listing is anecdotal, but in a representative way illustrates
the  importance of a correctly formed transmission (TMD/NBD) interface for correct folding and trafﬁcking. A comprehensive publication comprising more than 120 folding
deﬁcient mutations is in preparation.
a Most frequent mutants in European population with close to 60% of patients harboring either one or both variants.
b Most frequent mutation found in at least one allele of 90% of cystic ﬁbrosis patients.
c Allelic frequency of about 30% in the Asian population.
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onﬁrmed for other ABC exporters shows a remarkable hallmark.
n contrast to the side-by-side arrangement of TMDs and NBDs
bserved for ABC importers, efﬂux transporters show a domain
wapped architecture. While the ﬁrst intracellular loop of each
MD  forms contacts with the ipsilateral NBD, intracytoplasmic loop
 of each half reaches over to engage in interactions with the con-
ralateral NBD. Contacts are formed via four short -helices of 2–3
elical turns, the axis of which runs in parallel to the membrane-
riented surface of the NBDs. These helices, termed “coupling
elices” by Dawson and Locher [65] and Hollenstein et al. [70] con-
ribute to formation of the transmission interface, which connects
he nucleotide binding domains and the transmembrane domains.
oupling helices of the second intracellular loops come to rest in a
roove between -helical and core domain of the NBD on top of a
-strand, which precedes a loop region containing the eponymous
lutamine of the so called Q-loop, a hypothetical sensor of cleavage
f the ATP - anhydride bond (Fig. 4). The rigid body movement
etween -helical and F1 type core domain of the respective NBD
an be envisioned to affect positioning of these second coupling
elices, which in turn act as levers transmitting the conformational
hange induced by ATP binding and hydrolysis to the membrane
panning portion of the transporter. Correct positioning of ICLs 2
nd 4 as outlined above, can be assumed to represent a central step
n adopting a fully folded state and any mutations of residues that
ie close to this interface might turn it into an Achilles heel that
ffects architecture of ABC-transporters on a larger scale. Although
olding trajectories are only partially understood, cornerstones of
he folding process have been deﬁned: (i) As illustrated above in
he discussion of the Levinthal paradoxon, sampling of all possible
onformational states is not a viable biological option for achieving
he correctly folded state of a protein. Rather, a sequence of timed
vents along folding trajectories is required to occur during the
roduction of a correctly folded and functional protein. (ii) Folding
f individual domains precedes positioning of these domains
elative to each other (also referred to as superfolding). Evidence
uggests that translational pausing at rare codons might provide a
ime delay to enable independent and sequential folding of deﬁned
ortions of the nascent polypeptide chain, i.e. rare codons are
requently found at C-terminal ends of domains or subdomains.
hese provide a short respite period for folding, before synthesis
f the protein chain of subsequent domains is initiated [71]. For
 half transporter consisting of two monomers, each containing a
ingle TMD  and NBD, insertion of coupling helix 2 in the NBD of
 second monomer is likely to require completion of the synthesis
f the entire monomer. Similarly, for full transporters, it might
e assumed that completion of the entire sequence is likely to
recede engagement of ICLs2/4 in the respective NBDs of the
ther half of the transporter. (iii) Conformational changes at the
ransmission interface of an ABC transporter are a prerequisite for
unction. On the other hand, folding requires deﬁned interactions
t this interface, which are able to confer necessary stability.
he following lines of evidence indicate that interactions at the
ransmission interface are critical: (i) Different ABC transporters
how missense mutations in similar or identical positions along
his domain interface, which are capable of inducing incomplete
olding. These mutations frequently affect the NBD -helical and
ore domains as well as the intracellular contact loops in regions
hat are either close to the coupling helices or lie within them.
able 2 contains a list of representative mutations, their location
ithin the protein and diseases associated with these mutations.
A similar clustering of disease-linked mutations has been
bserved for G-protein coupled receptors [84], suggesting that
utations in protein families occur in structurally similar or
ven identical positions. These positions are prone to result in
alfunction, which is rooted in the common fold (molecular archi-
ecture) of the protein family. Only secondary to this underlyingResearch 83 (2014) 63–73
fold-determined cause of disease is the associated phenotype,
which is determined by the physiological role that the individ-
ual member of the protein family plays. The word “phenotologous
sites” or “disease phenotology” has been suggested by the group
of Sanders to signify this circumstance [84]. (ii) Active site com-
pounds rescue folding deﬁcient mutants in the -helical domain
of the NBDs. The distance between the active site and the mutated
residue in the NBD of approximately 60 A˚ indicates a long-range
effect (Fig. 4). Mechanistically, the ability of active site compounds
to rescue NBD mutants can be explained by the fact that both the
formation of the active site and the transmission interface are con-
tingent on correct positioning of the second intracytoplasmic loops
(Spork, Sohail, Chiba, in preparation). (iii) Mutations in the active
site lead to decreased binding afﬁnity of active site compounds
and decreased ability to rescue trafﬁcking (Spork, Sohail, Chiba,
unpublished).
1.6. Candidates for trafﬁcking rescue in the family of ABC proteins
It has been well appreciated that only a fraction of wild
type CFTR (cystic ﬁbrosis transmembrane conductance regulator)
reaches the membrane of airway epithelial cells and exocrine
glands and that CFTR type 2 mutations lead to an even further
impairment of trafﬁcking [85–88]. In recent years evidence has
accumulated that not only folding of CFTR, but also of other
ABC proteins is frequently affected by nonsynonymous muta-
tions and that incomplete folding is related to a number of
human diseases. These include ABCA1 (HDL-deﬁciency, Tangier dis-
ease) [89,90], ABCB4 (progressive familial intrahepatic cholestasis
type 3; PFIC3) [91], ABCB11 (PFIC2) [92], ABCC2 (Dubin-Johnson
syndrome) [93,94], ABCC6 (pseudoxanthoma elasticum, general
arterial calciﬁcation of infancy) [95] and ABCG2 (gout) [96]. A
systematic survey of non-synonymous mutations indicates that
misfolding as an underlying mechanism of ABC protein deﬁcien-
cies might be more prevalent than expected. Evidence for the
effect of mutations and non-synonymous SNPs on protein trafﬁck-
ing, maturation, or ER associated degradation has been provided
for at least the following members of the human ABC family:
ABCA1, ABCA3, ABCA4, ABCB1, ABCB4, ABCB11, ABCC2, ABCC4,
ABCC7, ABCC8, ABCC11 and ABCG2 (reviewed in Nakagawa et al.
[97]). Undoubtedly, ubiquitin-mediated proteasomal degradation
of ABC transporters due to incomplete folding is recognized as an
important pathogenetic principle for diseases associated with ABC
protein deﬁciency beyond the well-appreciated paradigm of cystic
ﬁbrosis.
1.7. Rescue of trafﬁcking by chemical and pharmacological
chaperones
Because of the recent successful market introduction of a small
molecule potentiator of CFTR (Ivacaftor, VX-770) [98], combina-
tions with a pharmacological chaperone (Lumacaftor, VX-809, CID
16678941) are now studied in a clinical setting in patients carry-
ing the frequent deltaF508 allele [99]. Because of a large number of
ongoing industrial and academic ventures focusing on the develop-
ment of folding correctors for CFTR, a separate article in this issue
is dedicated particularly to the treatment of cystic ﬁbrosis.
Low molecular weight compounds with an ability to rescue
trafﬁcking deﬁcient ABC proteins other than CFTR have been iden-
tiﬁed. These include chemical chaperones such as DMSO, glycerol,
trimethylamine-N-oxide (TMAO) and 4-phenyl butyrate (4-PB).
The latter is approved as a therapeutic agent for disorders of the
urea cycle and used as a candidate chemical chaperone in clinical
studies. A recent case study indicates the therapeutic potential of
4-PB to improve the clinical condition of a patient suffering from
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rogressive familial intrahepatic cholestasis type II, caused by a
olding deﬁciency of the bile salt export pump [100].
Speciﬁc and nontoxic pharmacological chaperones can be used
t much lower concentration than chemical chaperones. In vitro
xperiments suggest that breast cancer related protein (BCRP)
101], CFTR (ABCC7) [102,103], MRP1 (ABCC1) [104], ABCB1 and
UR1 (ABCC8) can be rescued by small molecules.
Misfolding/incomplete folding is thus a signiﬁcant cause of dis-
ase and development of small molecules that correct surface
xpression and by that enhance transport activity, has been ini-
iated for several ABC proteins. These include the bile salt export
ump (BSEP, ABCB11), which is rate limiting for bile ﬂux. Both,
atural bile acids, in particular chenodeoxycholic acid (CDCA, CID
0133) and the non-steroidal farnesoid-X-receptor (FXR) agonist
W4064 (CID 9893571), as well as derivatives lacking FXR-agonist
ctivity were able to enhance function of the trafﬁcking deﬁcient
ESP mutant E297G, likely by increasing the amount of protein at
he plasma membrane [105–108].
Similarly, rescue of the folding deﬁcient ABCB4 variant I541F,
 phospholipid transporter associated with progressive familial
ntrahepatic cholestasis type 3, by cyclosporine A (CID 5284373)
as been reported in an in vitro setting [75]. An additional trans-
orter, which may  be amenable to pharmacochaperone treatment
s ABCC6. Mutations in this transporter are causally related to aber-
ant trafﬁcking, giving rise to a disease known as pseudoxanthoma
lasticum [95]. Furthermore, pharmacochaperones have been sug-
ested as a treatment option in gout cases caused by incomplete
olding and decreased functional activity of the ABCG2 variant
141K [96]. Here, compound VRT-325 (CID 11957831), initially
iscovered in a high-throughput screen to identify molecules that
ould correct mutant CFTR, was shown to increase levels of mature
ully glycosylated protein.
Notably, some of these studies indicate that small molecules,
hich bind to the membrane spanning portions of the transporters,
re capable of correcting mutations in spatially separated intracel-
ular domains and NBDs. The membrane spanning portion confers
ubstrate speciﬁcity and thus represents the most diverse regions in
ultiple sequence alignments of the protein family. Hence, expec-
ations are tied to the use of substrate analogs or derivatives that
ddress these diverse substrate sites of the transporters and exploit
heir capability of exerting long range corrector effects within the
rotein to keep off target effects to a minimum. It is, however,
nevitable that some of these correctors will also elicit untoward
ffects by acting as substrates and/or inhibitors of the very trans-
orter that they are designed to rescue. In addition, blockage of
elated transporters is to be anticipated, because several ABC trans-
orters have overlapping substrate speciﬁcities. However, these
roblems may  be obviated by using correctors that have short
alf-lives. Other, strategies are also conceivable (i.e., allosteric cor-
ectors).
. Concluding remarks
Rescue of trafﬁcking deﬁcient mutants by either chemical or
harmacological chaperones has emerged as a promising treat-
ent concept for monogenic diseases associated with SLC6 and
BC transporter malfunction. ER-checkpoints equate correct fold-
ng to proper function. Using this surrogate, they efﬁciently screen
bout 6000 membrane proteins (encoded by the human genome)
nd assure their quality prior to their further processing along the
ecretory pathway. The concept that folding of mutated proteins
ay be corrected by small molecules relies on the assumption that
he reverse equation (i.e., impaired folding = inactive protein) does
ot always hold true. While mutant proteins are in their nascent
tate, pharmacochaperones may  escort them past checkpoints ofResearch 83 (2014) 63–73 71
the ER quality control system and by that allow them to reach
their ﬁnal cellular destination. Indeed experimental evidence has
been provided that residual function is associated with a larger
number of folding deﬁcient transporter mutants and that this resid-
ual function may  sufﬁce to alleviate disease symptoms. Though
mutations affecting functional motifs of transporters cannot be cor-
rected, available evidence indicates these mutations to be by far
outnumbered by non-synonymous mutations in similar positions
of structurally related members of protein families. We  therefore
propose that critical regions in the 3D structure of SLC6 and ABC
transporters exist, which represent Achilles’ heels in the folding
process. If, as indicated, a common structural basis indeed exists,
correctors should be expected to show activity in more than one
folding deﬁcient mutant.
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